Navigation Links
Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Date:2/5/2008

SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) will announce financial results for the fourth quarter and year ended 2007 after the markets close on Monday, February 11, 2007 and will hold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva's management team will discuss financial results from the fourth quarter and full year 2007 as well as provide an overview of the company's product pipeline, recent events and milestones.

Interested parties can listen to the live audio webcast by dialing (800) 340-6289 (international dial: (706) 634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

Anesiva further announced that company management will present at the following events in February 2008:

-- BIO CEO & Investor Conference

Feb. 13, 2008 1:15 p.m. Eastern Time

Presentation:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ANSV&item_id=1 752218

-- Roth Capital Partners 20th Annual Growth Stock Conference

Feb. 21, 2008 9 a.m. Pacific Time

Presentation: http://www.rothcp.com/main/Page.aspx?PageID=7010

Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Anesiva's website at http://www.anesiva.com. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 ... genomic services and solutions with cutting edge next-generation sequencing ... completed a USD $75 Million [515 Million RMB] B ... International Capital Management ( Shenzhen ) Co., ... ("SDIC Innovation") and Shanghai Sigma Square Investment Center LP ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal ... the latest FDA guidance on pharmaceutical cocrystals as drug substance . The ... , The event follows the successful November 15th event that took place in ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the development of a new orally administered treatment for Alzheimer’s disease (AD), today ... of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s ...
Breaking Biology Technology:
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):